Arthur Pappas (Observer)

Contact Arthur

Art founded Pappas Capital in 1994, and over the past two decades the firm has managed more than $535 million in capital and invested in more than 70 life science companies.

Prior to founding Pappas Capital, Art had over 30 years of operating experience as a pharmaceutical and biotechnology industry executive,  holding  senior level leadership positions at several multinational pharmaceutical companies including Glaxo Holdings PLC, Abbott International, Merrell Dow Pharmaceuticals, and the Dow Chemical Company.

Art currently serves as a Director for Aura Biosciences and OrphoMed, and as a Board Observer for Amplyx Pharmaceuticals and Kezar Life Sciences.  He previously served as Chairman for CoLucid Pharmaceuticals, and on the boards of Afferent Pharmaceuticals, Chimerix, Quintiles Transnational Corp., TYRX, Syntonix Pharmaceuticals, LEAD Therapeutics, CardioDx, and Embrex.  He also serves on several non-profit boards, including the North Carolina Biotechnology Center, the Medical University of South Carolina Foundation for Research Development, The Wistar Institute, the Duke Cancer Institute, and the BioExec Institute.  He is a Member of the CEO Roundtable on Cancer and BayHelix.

Art is a decorated Vietnam veteran, having served as an officer in the US Army 101st Airborne Division. Art received a BS in Biology from Ohio State University and an MBA in Finance from Xavier University.

Our Team

Norman Selby

Executive Chairman

Norman C. Selby has spent 35 years in the healthcare world in a variety of consulting, managerial, investor and Board roles...

read full biography >

Roger Longman

Chief Executive Officer

Mr. Longman is recognized as an expert in biopharmaceutical strategy and reimbursement and often speaks at key...

read full biography >

Susan Raiola


Susan Raiola is the President of Real Endpoints. Ms. Raiola has over 10 years of experience in the pharmaceutical consulting...

read full biography >

Jane F. Barlow, MD

EVP & Chief Clinical Officer

Before starting her own firm, Dr. Barlow served as Associate Chief Medical Officer for CVS Health...

read full biography >

Beth Nash, MD

Chief Medical Officer

Dr. Beth Nash is Chief Medical Officer at Real Endpoints, where her team of pharmacists and biostatisticians has developed...

read full biography >

Laura Farmer

SVP, Business Development and Marketing

Laura Farmer leads business development and marketing for Real Endpoints and subsidiary, Reimbursement Intelligence...

read full biography >

Jane Borne, RPh

VP, Pharmacy

Jane Borne, RPh, is responsible for ensuring the clinical credibility and evidence basis of all RE drug evaluation activities...

read full biography >

Heather Ritchie

VP, Product Strategy and Development

Heather Ritchie is VP Product Strategy and Development at Real Endpoints. She works closely with our customers and partners...

read full biography >

Amy Steinkellner, PharmD

Senior Consultant

Amy Steinkellner, PharmD, has worked with the Real Endpoint team since 2012. She serves as senior clinical advisor to the research...

read full biography >

Robert Galvin, MD

Dr. Robert Galvin is the Chief Executive Officer of Equity Healthcare (EH), which oversees the management of health care for firms...

read full biography >

Michael Sherman, MD

Dr. Michael Sherman serves as Chief Medical Officer and senior vice president for Harvard Pilgrim Health Care...

read full biography >

Dennis Purcell

Dennis is the Founder, Senior Advisor, and previous Senior Managing Partner of Aisling Capital LLC.,  a leading investment firm...

read full biography >

Linda Blackerby

Linda has been serving as the President of Pharma Intelligence at Informa since May 2015, overseeing an income statement...

read full biography >

Arthur Pappas (Observer)

Art founded Pappas Capital in 1994, and over the past two decades the firm has managed more than $535 million in capital...

read full biography >